| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
First study included 57 patients with codeleted gliomas. No significant difference was observed in the overall survival of the patients with respect to age, degree of resection, maximum tumor diameter,histological subtype, and MGMT promoter methylation status. Gain of chromosome 19p and grade III histology were associated with shorter OS and they might be negative prognostic factors for the patients with gliomas showing total 1p19q loss.
Second study included 13 patients with brain tumors manifested or progressed during pregnancy. Expression of VEGFR-1/2, EGFR and c-Myc were observed regardless of the stage of pregnancy. Sex hormone receptors and HER-2 were mainly expressed in the tumors progressed during the postpartum. There was no specific CNAs shared between the pregnancy-associated brain tumors. However, it should be noted that an anaplastic astrocytoma with IDH mutation progressed from the precedent grade 2 tumors showed numerous CNAs including amplification of the c-Myc locus.
|
